Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance
November 12, 2010
Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance
Despite a 74-percent increase in OVA1 test volume over the second quarter, company officials lowered their 2010 guidance from 8,000 to 10,000 OVA1 sales to a range of 5,000 to 5,500 sales for the year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor - Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor - Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010 / ProteoMonitor - Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Presents Protein Biomarker Study Supporting OVA2 Ovarian Cancer Test
March 11, 2011 / ProteoMonitor